Hyperaldosteronism

Introduction and Pathophysiology

• Aldosterone is a mineralocorticoid hormone normally synthesized and secreted by the zona glomerulosa cells of the adrenal cortex in response to depleted intravascular volume via the renin-angiotensin system, or in response to high plasma potassium concentrations.
• Primary aldosteronism encompasses a heterogeneous group of disorders characterized by the excessive and autonomous secretion of aldosterone, which occurs entirely independently of the renin-angiotensin system.
• The unchecked hypersecretion of aldosterone leads to excessive renal sodium reabsorption and potassium excretion, classically resulting in severe hypertension, hypokalemia, and the profound suppression of plasma renin activity.
• While primary aldosteronism accounts for approximately 10% of all secondary hypertension in adults, it is a rare but critical cause of severe, early-onset hypertension in the pediatric population.
• Beyond the immediate hemodynamic consequences of hypertension, chronic aldosterone excess serves as an independent risk factor for long-term cardiovascular disease and progressive renal damage due to the hormone's direct fibrotic and inflammatory effects on non-renal tissues.

Etiological Classification

Primary Hyperaldosteronism

• Unilateral aldosterone-producing adenomas (APAs), classically known as Conn syndrome, account for 30% to 40% of all primary aldosteronism cases, though they are exceptionally rare in prepubertal children.
• Bilateral idiopathic hyperaldosteronism is the most frequent etiology, accounting for 60% to 70% of cases; while generally considered a disease of adulthood, it can present insidiously during childhood or adolescence.
• Primary nodular adrenal hyperplasia is another established cause of autonomous aldosterone secretion.
• Familial hyperaldosteronism (FH) encompasses several distinct monogenic syndromes (Types I through IV) that present with primary aldosteronism in pediatric patients.
• Glucocorticoid-remediable aldosteronism (GRA), which constitutes FH Type I, is a unique autosomal dominant condition caused by a chimeric gene fusion that places aldosterone synthesis under the ectopic regulatory control of adrenocorticotropic hormone (ACTH).

Secondary Hyperaldosteronism

• Secondary hyperaldosteronism is a physiological, compensatory response resulting from factors that appropriately activate the renin-angiotensin system.
• Systemic causes include decreased effective intravascular volume seen in congestive cardiac failure, nephrotic syndrome, and chronic liver disease.
• Renovascular causes include renal artery stenosis and rare renin-secreting juxtaglomerular tumors.
• Other common pediatric settings for secondary hyperaldosteronism include profound sodium loss due to renal tubular acidosis, chronic treatment with loop or thiazide diuretics, salt-wasting nephritis, or severe hypovolemia.

Genetic and Molecular Basis

Somatic Mutations in Aldosterone-Producing Adenomas

• Recent genomic studies have identified recurrent somatic mutations in the KCNJ5 gene (also known as Kir3.4) in approximately 38% of all APAs.
• The KCNJ5 gene encodes a G protein–gated inward rectifier potassium channel; specific mutations (such as G151R or L168R) profoundly alter the ion selectivity filter of this channel.
• This altered selectivity causes an abnormal influx of sodium, leading to permanent depolarization of the zona glomerulosa cell membrane.
• Membrane depolarization subsequently activates voltage-gated calcium channels, causing an influx of intracellular calcium that provides the primary signal for unchecked aldosterone production and cellular proliferation.
• Additional recurrent somatic mutations driving APAs have been identified in ATP1A1 (encoding the alpha subunit of the Na+/K+ ATPase), ATP2B3 (encoding a calcium ATPase), and CACNA1D (encoding a voltage-sensitive calcium channel).
• Many APAs also harbor pathogenic variants that directly activate the Wnt/beta-catenin signaling pathway, either through mutations in the CTNNB1 gene itself or in the APC gene.

Familial Hyperaldosteronism (FH) Subtypes

• FH Type I: Synonymous with GRA, this autosomal dominant disorder presents with severe hypertension in the first two decades of life.
• FH Type II: This autosomal dominant form is caused by germline mutations in the CLCN2 gene (which encodes the voltage-gated chloride channel ClC-2) and clinically resembles sporadic primary aldosteronism.
• FH Type III: Associated with germline mutations in the KCNJ5 gene, this severe variant classically presents in early childhood with massive bilateral adrenal hyperplasia, severe refractory hypertension, and profound hypokalemia.
• FH Type IV: Caused by germline mutations in CACNA1H (encoding the alpha subunit of the T-type calcium channel CaV3.2), this form typically presents with primary aldosteronism during the first decade of life.
• In rare instances, de novo germline mutations in CACNA1H can manifest as a complex syndromic presentation featuring early-onset primary aldosteronism, cerebral palsy, epilepsy, and severe neurological abnormalities.

Specifics of Glucocorticoid-Remediable Aldosteronism (GRA)

• GRA is an autosomal dominant form of low-renin hypertension characterized by the unique phenomenon wherein hyperaldosteronism is rapidly and completely suppressed by the administration of exogenous glucocorticoids.
• The molecular pathogenesis involves an unequal chromosomal crossover event during meiosis that creates a hybrid CYP11B1/CYP11B2 gene.
• This chimeric gene fuses the ACTH-responsive promoter region of CYP11B1 (11-beta-hydroxylase) with the coding sequence of CYP11B2 (aldosterone synthase), causing aldosterone to be synthesized in the zona fasciculata under the control of ACTH rather than angiotensin II.
• The aberrant enzymatic activity leads to the massive overproduction of the hybrid steroids 18-hydroxycortisol and 18-oxocortisol, because their synthesis requires both 17-alpha-hydroxylase activity (exclusive to the fasciculata) and aldosterone synthase activity.
• A strong family history of early-onset hypertension or premature cerebrovascular accidents (strokes) in young relatives is a classic historical clue demanding evaluation for GRA.

Clinical Manifestations

• The clinical presentation of primary aldosteronism in children exists across a continuum of severity, ranging from entirely asymptomatic patients to those in hypertensive crisis.
• Early in the disease course, children may present solely with incidentally discovered moderate hypertension (typically 30 mm Hg higher than unaffected family members of the same age) without overt hypokalemia or demonstrably low renin activity.
• More severe presentations feature extreme, sustained hypertension (with blood pressures documented up to 240/150 mm Hg), frequently accompanied by severe headaches, dizziness, and visual disturbances.
• Chronic hypokalemia leads to a state of nephrogenic diabetes insipidus, manifesting clinically as marked polyuria, nocturia, secondary enuresis, and compensatory polydipsia.
• Neuromuscular manifestations driven by the profound hypokalemia and alkalosis include severe muscle weakness, muscle discomfort, intermittent paralysis, marked fatigue, and clinical tetany.
• Chronic pediatric primary aldosteronism can also lead to significant failure to thrive and a striking deceleration in linear growth.

Diagnostic Evaluation and Laboratory Findings

Biochemical and Electrolyte Profile

• The classic biochemical signature of advanced primary aldosteronism comprises hypertension, hypokalemic metabolic alkalosis, and suppressed plasma renin activity.
• Serum potassium is frequently depleted, though this is not a universally consistent finding; normokalemic primary aldosteronism is increasingly recognized, particularly in early or mild disease.
• Acid-base evaluation classically reveals a metabolic alkalosis characterized by an elevated serum pH and increased serum carbon dioxide concentrations.
• Serum sodium levels are typically maintained in the upper normal range or are frankly elevated (hypernatremia), while serum chloride and magnesium concentrations are frequently decreased.
• Importantly, serum total and ionized calcium concentrations remain strictly normal, even in children presenting with carpopedal spasms or tetany.
• Urinalysis demonstrates a neutral or alkaline pH with an inappropriately high rate of urinary potassium excretion despite the presence of systemic hypokalemia.
• Plasma levels of aldosterone may be distinctly elevated or paradoxically fall within the upper limits of the normal range; however, aldosterone concentrations measured in a 24-hour urine collection are universally increased.
• Plasma renin activity (PRA) or direct renin levels are persistently suppressed and fail to rise appropriately in response to physiological stimuli such as upright posture or salt restriction.

Specialized Testing and Imaging

• In patients suspected of having GRA, specialized biochemical testing reveals markedly increased urinary and plasma levels of 18-oxocortisol and 18-hydroxycortisol.
• A formal high-dose dexamethasone suppression test is diagnostically definitive for GRA; the administration of dexamethasone rapidly decreases aldosterone levels and resolves both clinical and laboratory features, whereas it has absolutely no suppressive effect in classic sporadic primary hyperaldosteronism.
• Definitive diagnosis of GRA and other familial forms is established by demonstrating the chimeric CYP11B1/CYP11B2 gene or specific germline mutations via molecular genetic testing.
• Following biochemical confirmation of primary aldosteronism, high-resolution adrenal imaging (Computed Tomography or Magnetic Resonance Imaging) is mandatory to differentiate between a unilateral aldosterone-producing adenoma and bilateral adrenal hyperplasia.
• Patients who present with a highly suspicious clinical picture (hypertension and suppressed renin) but equivocal baseline aldosterone levels require formal dynamic testing in a clinical research setting, utilizing intravenous saline loading to definitively confirm the autonomous, non-suppressible nature of the aldosterone secretion.

Differential Diagnosis

• The primary diagnostic challenge is differentiating autonomous primary aldosteronism from physiologic secondary hyperaldosteronism, which typically presents with appropriately elevated plasma renin activity.
• The differential diagnosis for severe, low-renin childhood hypertension with hypokalemia includes the Syndrome of Apparent Mineralocorticoid Excess (AME), an autosomal recessive disorder caused by a deficiency in the 11-beta-hydroxysteroid dehydrogenase type 2 enzyme, which fails to inactivate cortisol to cortisone. In AME, both renin and aldosterone are profoundly suppressed.
• Liddle syndrome, an autosomal dominant disorder caused by activating mutations in the epithelial sodium channel, presents with a clinical and biochemical phenotype identical to primary aldosteronism, but is distinguished by the complete suppression of both plasma renin activity and serum aldosterone levels.
• Specific variants of Congenital Adrenal Hyperplasia (CAH) must be excluded; 11-beta-hydroxylase deficiency and 17-alpha-hydroxylase deficiency both present with severe hypertension, hypokalemia, and suppressed renin/aldosterone due to the massive accumulation of the alternative mineralocorticoid precursor deoxycorticosterone (DOC).

Management and Treatment Strategies

Medical Management

• For children with primary aldosteronism secondary to bilateral idiopathic adrenal hyperplasia, rigorous dietary salt restriction is a mandatory foundational component of chronic management.
• The primary pharmacological intervention for bilateral hyperplasia is mineralocorticoid receptor antagonism, most commonly utilizing spironolactone administered at a dose of 1 to 3 mg/kg/day, titrated up to a maximum of 100 mg/day.
• While spironolactone effectively normalizes blood pressure and corrects hypokalemia, its inherent non-specific antiandrogenic properties frequently cause unacceptable side effects (such as painful gynecomastia and delayed maturation) in pubertal males.
• Eplerenone is a highly specific mineralocorticoid receptor antagonist that lacks these antiandrogenic side effects and serves as an excellent, safer alternative in the pediatric and adolescent populations; it is typically dosed at 25 to 100 mg/day in two divided doses.
• As an alternative or adjunct therapy, epithelial sodium channel blockers such as amiloride or triamterene can be effectively employed to manage renal potassium wasting and hypertension.
• In patients with GRA, the highly specific treatment of choice is the daily administration of a glucocorticoid (such as dexamethasone at a dose of 25 µg/kg/day in divided doses, or physiological hydrocortisone) to chronically suppress pituitary ACTH secretion and halt aberrant aldosterone synthesis.
• If the hypertension in a GRA patient is severe or long-standing, physiological glucocorticoid replacement alone may fail to normalize blood pressure, necessitating the addition of potassium-sparing diuretics (spironolactone, eplerenone) or calcium channel blockers.

Surgical Management

• In patients diagnosed with a unilateral aldosterone-producing adenoma (Conn syndrome), surgical resection is the definitive and curative treatment of choice.
• Laparoscopic unilateral adrenalectomy is the universally preferred surgical approach for these benign tumors.
• Successful, highly selective surgical enucleation (cortical-sparing surgery) of the aldosterone-producing adenoma has also been reported, preserving the remaining normal adrenal cortical tissue.
• In extreme cases of bilateral idiopathic hyperaldosteronism or severe familial hyperaldosteronism that prove entirely refractory to maximal multi-drug medical management, a unilateral or subtotal adrenalectomy may be considered as a salvage procedure to mitigate life-threatening cardiovascular and neurological complications.